# # # #
Today’s post involves a product from a company. The SoPD has not had any contact with the company or associated parties. This post should not be considered as an endorsement or an advertisement of the product. Recently published results from a clinical trial were interesting enough to stimulate this discussion.
Omega-3 and omega-6 represent two families of fatty acids that have important biological functions in our bodies. A careful balance of them is required in our diets in order for us to function normally.
A recent report from a small clinical trial indicates that daily supplementation with a formulation that includes these molecules could have beneficial effects in Parkinson’s motor symptoms.
In today’s post, we will discuss what omega-3 and omega-6 fatty acids are, we will review the new report outlining the study results, and discuss why these results could be interesting.
# # # #
Back when I was young and less beautiful, I had a formidable appetite.
Seriously. My consumption rate was the stuff of legend. There were local all-you-can-eat restaurants that would refuse to serve me, for fear that I would liquidate them.
But I am man enough to admit that I was nothing compared to my friend Jason’s younger brother “Peter”.
One day the three of us went down to the local MacDonald’s during one of their promotions (something like 50 cents per Big Mac) and we challenged ourselves to see who could eat the most. Jason sensibly stopped after finishing 3 burgers, while I had to finally throw in the towel on my 6th burger (to be honest I was struggling from burger #4).
Jason and I had to ask Peter to stop on burger #9.
I kid you not.
Think about that for a second: NINE Big Macs!
We were watching in bloated horror as this skinny teenage kid was just sitting there – with a milk shake in one hand – throwing back these burgers like they were nothing. Even now it is grotesque to reminisce about, and I really wonder if we didn’t do serious damage to our livers that day.
That is disgusting. What does it have to do with Parkinson’s?
Well, we all do silly things when we are young and invincible. At that age it seems like you can eat whatever you want and there are no consequences. But of course as we get older, we need to start carefully considering what you are putting into your body.
And recently the results of a clinical study were published that indicate that what we consume could also influence the course of Parkinson’s.
What do you mean?
Continue reading “Omega+omega=a mega result?”
# # # #
Alpha synuclein is considered to be an influential factor in Parkinson’s. It is a protein that accumulates and clumps together inside certain nerve cells in many cases of Parkinson’s.
Recently, clinical trials have attempted to target alpha synuclein that is floating around outside of cells. Some of the strategies focus on an approach called ‘immunotherapy’, which involves boosting the immune system to help remove the toxic form of this protein from the body.
This week, one biotech company – AC Immune – bought the Parkinson’s-associated immunotherapy assets off another biotech company – AFFiRiS – which has been developing a potential vaccine for Parkinson’s.
In today’s post, we will discuss what immunotherapy is, look at how AFFiRiS has been trying to apply it to Parkinson’s, and review what AC-Immune plans to do next.
# # # #
AC Immune is a a Switzerland-based biotech company that was foundered in 2003.
They are focused on “improving the lives of patients suffering from Alzheimer’s and other neurodegenerative diseases” (Source).
Their approach has primarily centered around the development of immunotherapy approaches. And this week they made a very interesting announcement.
What is immunotherapy?
Continue reading “AC Immune acquires assets of AFFiRiS”
The great ice hockey player Wayne Gretzky once said “A good hockey player plays where the puck is. A great hockey player plays where the puck is going to be” (the original quote actually came from his father, Walter).
At the start of each year, it is a useful practise to layout what is planned for the next 12 months. This can help us better anticipate where ‘the puck’ will be, and allow us to prepare for things further ahead.
2017 was an incredible year for Parkinson’s research, and there is a lot already in place to suggest that 2018 is going to be just as good (if not better).
In this post, we will lay out what we can expect over the next 12 months with regards to the Parkinson’s-related clinical trials research of new therapies.
Charlie Munger (left) and Warren Buffett. Source: Youtube
Many readers will be familiar with the name Warren Buffett.
The charming, folksy “Oracle of Omaha” is one of the wealthiest men in the world. And he is well known for his witticisms about investing, business and life in general.
Warren Buffett. Source: Quickmeme
He regularly provides great one liners like:
“We look for three things [in good business leaders]: intelligence, energy, and integrity. If they don’t have the latter, then you should hope they don’t have the first two either. If someone doesn’t have integrity, then you want them to be dumb and lazy”
“Work for an organisation of people you admire, because it will turn you on. I always worry about people who say, ‘I’m going to do this for ten years; and if I really don’t like it very much, then I’ll do something else….’ That’s a little like saving up sex for your old age. Not a very good idea”
“Choosing your heroes is very important. Associate well, marry up and hope you find someone who doesn’t mind marrying down. It was a huge help to me”
Mr Buffett is wise and a very likeable chap.
Few people, however, are familiar with his business partner, Charlie Munger. And Charlie is my favourite of the pair.
Continue reading “The road ahead: Parkinson’s research in 2018”